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Abstract: The transplantation of organs and cells from pigs into humans could overcome the 
critical and continuing problem of the lack of availability of deceased human organs and cells for 
clinical transplantation. Developments in the genetic engineering of pigs have enabled consider-
able progress to be made in the experimental laboratory in overcoming the immune barriers to 
successful xenotransplantation. With regard to pig organ xenotransplantation, antibody- and cell-
mediated rejection have largely been overcome, and the current major barrier is the development 
of coagulation dysregulation. This is believed to be due to a combination of immune activation 
of the vascular endothelial cells of the graft and molecular incompatibilities between the pig and 
primate coagulation–anticoagulation systems. Pigs with new genetic modifications specifically 
directed to this problem are now becoming available. With regard to less complex tissues, such 
as islets (for the treatment of diabetes), neuronal cells (for the treatment of  Parkinson’s disease), 
and corneas, the remaining barriers are less problematic, and graft survival in nonhuman primate 
models extends for .1 year in all three cases. In planning the initial clinical trials, consideration 
will be concentrated on the risk–benefit ratio, based to a large extent on the results of preclinical 
studies in nonhuman primates. If the benefit to the patient is anticipated to be high, eg, insulin-
independent control of glycemia, and the potential risks low, eg, minimal risk of transfer of a 
porcine infectious agent, then a clinical trial would be justified.
Keywords: infection, pigs, genetically-engineered, xenotransplantation, islets,  xenotransplantation, 
organs
Introduction
In the developed world, there is a critical shortage of organs and cells from deceased 
human donors for the purposes of transplantation. For example, in the US, there are 
more than 110,000 patients awaiting an organ or cell transplant of one type or another, 
and yet each year only about 30,000 organs become available from approximately 8000 
deceased donors. Despite immense efforts over the past 50 years, we are no closer to 
resolving the problem of donor organ availability than we were at the beginning of this 
period. The steadily improving results of allotransplantation have led to an increasing 
number of patients being put on the waiting list for these procedures.
This problem could be resolved if we were able to use a readily available animal as a 
source of organs and cells for transplantation into humans.1 Indeed, xenotransplantation 
has several advantages over allotransplantation (Table 1). The pig has been identified 
as a potential source of organs and cells for this purpose (Table 2).2 Considerable 
progress has been made in overcoming the immunological barriers to successful pig 
organ and cell transplantation in primates, though some barriers remain.3
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Table 2 Advantages and disadvantages of the pig as a potential source of organs and cells for humans, in contrast with those of the 
baboon in this role
Pig Baboon
Availability Unlimited Limited
Breeding potential Good Poor
Period to reproductive maturity 4–8 months 3–5 years
Length of pregnancy 114 ± 2 days 173–193 days
Number of offspring 5–12 1–2
Growth Rapid (adult human size within 6 months)** Slow (9 years to reach maximum size)
Size of adult organs Adequate Inadequate*
Cost of maintenance Significantly lower High
Anatomical similarity to humans Moderately close Close
Physiological similarity to humans Moderately close Close
Relationship of immune system to humans Distant Close
Knowledge of tissue typing Considerable (in selected herds) Limited
Necessity for blood type compatibility with humans Probably unimportant Important
Experience with genetic engineering Considerable None
Risk of transfer of infection (xenozoonosis) Low High
Availability of specific pathogen-free animals Yes Yes
Public opinion More in favor Mixed
Notes: *The size of certain organs, eg, the heart, would be inadequate for transplantation into adult humans; **breeds of miniature swine are approximately 50% of the 
weight of domestic pigs at birth and sexual maturity, and reach a maximum weight of approximately 30% of standard breeds.
Table 1 Major advantages of xenotransplantation over 
allotransplantation
Unlimited supply of organs, tissues, and cells
Unlimited supply will allow transplantation procedures in ‘borderline’ 
candidates who might otherwise be declined
Organs available electively
Avoids the detrimental effects of brain death on donor organs
Provides exogenous infection-free sources of organs, tissues, and cells
Obviates the ‘cultural’ barriers to deceased human donation present in 
some countries, eg, Japan
History of xenotransplantation
The history of xenotransplantation has been fully reviewed.1,4 
Xenotransplantation has a long history in the clinic. In the 
eighteenth century, blood transfusions from animals to 
humans were attempted, and this practice continued intermit-
tently for 200 years, before it was realized that the results did 
not warrant the risks. The first corneal xenotransplant was 
carried out in 1838, more than 65 years before the first corneal 
allotransplant in 1905.5 Organs from nonhuman primates and 
nonprimate mammals were transplanted in a small number 
of patients in the early part of the twentieth century, with 
poor results1 (Table 3), although Reemtsma et al reported the 
survival of one patient with transplanted chimpanzee kidneys 
who returned to an active life for approximately 9 months 
until she suddenly died, probably from an acute electrolyte 
disturbance.6 In 1994, Groth and his colleagues carried out 
the transplantation of fetal porcine islets into patients with 
diabetes,7 though without clinical benefit.
Immune barriers
Pig organ xenotransplantation
When a pig organ is transplanted into a nonhuman  primate 
(or into a human), it is followed by hyperacute rejection 
(Figure 1). This is a consequence of binding of natural anti-
pig antibodies that are present in all humans to antigens on 
the surface of the pig vascular endothelial cells, activat-
ing complement, and causing rapid graft destruction. The 
most important target for human anti-pig antibodies is the 
galactose-α1,3-galactose (Gal) antigen,8–10 an oligosaccha-
ride very similar in structure to the B blood group antigen. 
The immunopathology of hyperacute rejection is very similar 
to that which occurs when organ allotransplantation is carried 
out across the ABO blood group barrier.11,12
If this can be prevented, it is usually followed within days 
or weeks by acute humoral xenograft rejection (sometimes 
known as acute vascular rejection or delayed xenograft 
rejection), which is a slower process, but which is again 
related to antibody binding, complement activation, and the 
activity of innate immune cells, such as macrophages and 
neutrophils.13
Hyperacute rejection has largely been overcome by the 
transplantation of organs from pigs that do not express the 
important Gal antigens (α1,3-galactosyltransferase gene-
knockout pigs),14–16 particularly if these also express one or 
more human complement-regulatory proteins, eg, CD46, 
CD55, CD59 (Table 4).17–21 The major target for anti-pig 
antibodies is therefore not present, although there is binding of 
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Table 3 Summary of clinical xenotransplantation of organs in the 
twentieth century
Donor n Survival
Kidney – primate (30) 1 day–9 months
   – nonprimate (3) 3–9 days
Heart – primate (5) ,1–20 days
    – nonprimate (4) ,1 day
Liver – primate (11) ,1–70 days
   – nonprimate (1) ,2 days
Copyright © 2012 The Royal College of Surgeons of England. Reproduced with permis-
sion of Taniguchi S and Cooper DKC (content has been modified in this article).101
Figure 1 Hyperacute rejection (defined as occurring within the first 24 hours after 
transplantation) of a pig heart in a baboon.
Complement-mediated injury associated with the immediate binding of natural anti-
pig antibodies to antigens expressed on the vascular endothelium of the pig organ, 
eg, Galα1-3Gal, results in disruption of the myocardial capillaries, with massive 
interstitial hemorrhage and edema.
antibodies to non-Gal antigenic targets,21–23 the nature of which 
is unknown at present24 except in one respect (see below). 
Nevertheless, the effect and extent of complement activation is 
reduced by the presence of the human complement-regulatory 
proteins. Acute humoral xenograft rejection can also be greatly 
inhibited when organs from these pigs are transplanted, but 
may not be completely prevented as the activity of the innate 
immune cells continues.13 The addition of potent immunosup-
pressive therapy, particularly including a costimulatory block-
ade agent,25 inhibits acute humoral xenograft rejection further, 
and graft survival of weeks or months can be achieved.26–31
Isolated acute cellular rejection, ie, T cell-mediated rejec-
tion, has rarely been seen after pig organ transplantation into 
nonhuman primates, either because acute humoral xenograft 
rejection intervenes or because the potent immunosuppres-
sive therapy successfully prevents this response. Graft athero-
sclerosis (chronic rejection), however, has been documented 
in hearts that have functioned for longer than approximately 
3 months in nonhuman primates (Figure 2).28,30
Table 4 Genetically modified pigs currently available for 
xenotransplantation research
Gal antigen deletion or ‘masking’
α1,3-galactosyltransferase gene-knockout (GT-KO)
Human H-transferase gene expression (expression of blood type O 
antigen)
Endo-beta-galactosidase C (reduction of Gal antigen expression)
Complement regulation by human complement-regulatory 
gene expression
CD46 (membrane cofactor protein)
CD55 (decay-accelerating factor)
CD59 (protectin or membrane inhibitor of reactive lysis)
Anticoagulation and anti-inflammatory gene expression  
or deletion
Human tissue factor pathway inhibitor (TFPI)
Human thrombomodulin
Human CD39 (ectonucleoside triphosphate diphosphohydrolase-1)
von Willebrand factor–deficient (natural mutant)
Suppression of cellular immune response by gene expression 
or downregulation
Porcine CTLA4-Ig (cytotoxic T-lymphocyte antigen 4 or CD152)
LEA29Y (inhibition of the B7/CD28 costimulatory pathway of T-cell 
activation)
CIITA-DN (MHC class II transactivator knockdown, resulting in swine 
leukocyte antigen class II knockdown)
Human TRAIL (tumor necrosis factor-alpha-related apoptosis-inducing 
ligand)
HLA-E/human β2-microglobulin (inhibits human natural killer cell 
cytotoxicity)
Human CD47 (for species-specific CD47-SIRP-alpha natural interaction 
on macrophages)
Human FAS ligand (CD95L)
Human GnT-III (N-acetylglucosaminyltransferase III)
Antiapoptotic gene expression
Human A20 (tumor necrosis factor-alpha-induced protein 3)
Human heme oxygenase-1 (HO-1)
Human TNFRI-Fc (tumor necrosis factor-alpha receptor I-Fc)
Prevention of porcine endogenous retrovirus (PERV) activation
PERV siRNA
Modified from Ekser et al3; pigs with combinations of genetic modification, eg, 
GT-KO with added transgenes, are available.
In summary, with organs from the current genetically 
engineered pigs and with potent immunosuppressive therapy, 
hyperacute rejection can largely be prevented and the onset 
of acute humoral and acute cellular rejection can be greatly 
delayed. However, activation of the vascular endothelium 
of the organ by anti-non-Gal antibodies and possibly innate 
immune cells results in the initiation of coagulation dysfunc-
tion in the graft. This takes the form of the development of a 
thrombotic microangiopathy in the small vessels of the graft 
and/or a systemic consumptive coagulopathy that results 
in spontaneous hemorrhage.30,32,33 Activation of recipient 
platelets by the presence of the graft endothelium occurs 
and is an initiating factor.34 Coagulation dysregulation can be 
reversed if the graft is excised before hemorrhage develops, 
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indicating that it is the presence of the xenograft that is the 
initiating factor.32
Coagulation dysfunction is almost certainly a combination 
of immune activation of the porcine vascular endothelium by 
anti-pig antibodies, complement, and innate immune cells, and 
the presence of several molecular incompatibilities between pig 
and primate that lead to a change in endothelial phenotype from 
anticoagulant to procoagulant.35–40 For example, pig thrombo-
modulin is not an efficient cofactor for thrombin’s activation 
of protein C, and pig von Willibrand factor is associated with 
excessive primate platelet aggregation.
Despite maximum heparin therapy or the administration 
of other anticoagulant or antithrombotic agents, thrombotic 
microangiopathy and consumptive coagulopathy have to date 
not been prevented. However, new genetic modifications of 
the organ-source pigs, including expression of an antithrom-
botic gene, such as thrombomodulin, tissue factor pathway 
inhibitor, or CD39, may resolve this problem (Table 4).3 
These pigs are just becoming available for testing in nonhu-
man primate models.
Thrombotic microangiopathy appears to be the dominant 
pathology after pig heart xenotransplantation  (Figure 3),28,30,31 
whereas consumptive coagulopathy occurs more rapidly after 
pig kidney xenotransplantation  (Figure 4).29,34 This difference 
in outcome may be related to differences in the vascular 
endothelium of the two organs.41 In our own experience, 
the more rapid development of consumptive coagulopathy 
results in a reduced period of survival of porcine kidneys in 
nonhuman primates. Whereas heterotopic heart grafts have 
functioned for 6–8 months,28,42 life-supporting kidney trans-
plants have not functioned for even 3 months.26,29 However, 
survival of life-supporting orthotopic heart grafts has also 
had a limited survival of less than 2 months,43,44 and so the 
difference in survival may not be great.
Despite adequate hepatic function,45,46 pig liver xenotrans-
plantation in a nonhuman primate is followed by a different 
form of coagulation dysfunction, namely by an immediate 
loss of platelets.47 The platelets probably sequestrate within 
the graft or maybe are phagocytosed by cells in the graft.48,49 
The profound thrombocytopenia results in life-threatening 
spontaneous hemorrhage into the tissues and from the body 
orifices within days.
The immune responses and coagulation dysregulation that 
are associated with pig heart or kidney xenotransplantation are 
very much accelerated after pig lung xenotransplantation.50,51 
Survival after pig lung transplantation in a nonhuman primate 
is therefore currently limited to hours or days.
It is hoped that further planned genetic modifications of 
the organ-source pigs will overcome most of these barriers 
(Table 4). The genetic modifications that we believe may be 
necessary to overcome these various immune and pathophysi-
ological barriers have recently been discussed in relation to 
xenotransplantation of the lung, in which these problems are 
particularly acute and vigorous.52
There is also a documented systemic inflammatory response 
to the presence of a pig organ xenograft,53 and again this may 
require genetic modification to the organ-source pig if it is to 
be prevented or minimized. Expression of thrombomodulin, 
CD39, heme oxygenase-1, or A20 may prove valuable (Table 4).
Pig cell xenotransplantation
The barriers associated with transplantation of less complex 
organs, such as the cornea or cells, eg, pancreatic islets 
or dopamine-producing neuronal cells, appear to be less 
Figure 3 Thrombotic microangiopathy in a pig heart transplanted into a baboon. 
Fibrin deposition and platelet aggregation results in thrombosis within the vessels of 
the graft. Minor pathological changes can be seen within a month (right); ischemic 
fibrosis occurs when the thrombosis becomes extensive (left).
Figure 2 Chronic rejection (graft atherosclerosis) in a vessel in a pig heart 
transplanted into a baboon 4 months previously (from Kuwaki K, et al31).
Copyright © 2012 John Wiley and Sons. Reproduced with permission of Kuwaki K, 
Knosalla C, Dor FJ, et al. Suppression of natural and elicited antibodies in pig-to-
baboon heart transplantation using a human anti-CD154 monoclonal antibody-based 
regimen. Am J Transplant. 2004;4(3):363–372.31
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problematic. With regard to islets and neuronal cells, the 
absence of a vascular endothelium in these transplants may 
be a major factor in their better outcome. However, there are 
still significant problems to be overcome.
With regard to pig islet transplantation, there is an initial loss 
of islets when they are infused into the portal vein (which is the 
current approach for islet allotransplantation). An inflammatory 
response is set up that leads to destruction of a significant percent-
age of the islets. This event, known as the instant blood-mediated 
inflammatory reaction (IBMIR)54–59 (reviewed in van der Windt 
et al60), is probably a combination of the effect of antibody bind-
ing to the grafts with subsequent activation of complement and 
coagulation and innate immune cells, and a nonspecific effect 
related to the (unnatural) presence of islets in the blood, which 
also leads to activation of complement and coagulation. It may 
therefore have both immune and nonimmune component mecha-
nisms; recent data suggest immune mechanisms are playing a 
greater role than hitherto thought.61 If sufficient islets remain 
functional, however, long-term (.1 year) correction of diabetes 
can be achieved as long as potent immunosuppressive therapy 
is continued; healthy-looking pig islets can be identified in the 
nonhuman primate liver (Figure 5).62–64 New genetically engi-
neered pigs with multiple gene modifications, some of which are 
specifically directed to protecting the islets from IBMIR (using 
an insulin promoter), are now becoming available.3
There is some evidence that neonatal pig islets may have 
some advantages over adult pig islets.65,66 Furthermore, in an 
effort to avoid the substantial loss of islets from IBMIR, efforts 
are being made to identify suitable sites for islet transplantation 
other than the portal vein (reviewed in van der Windt et al67).
Encouraging results have also been obtained when islets 
are transplanted within microcapsules that protect them 
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Figure 4 Correlation between platelet count and fibrinogen level (indicating the development of a consumptive coagulopathy) and tissue factor expression on platelets and 
peripheral blood mononuclear cells (PBMC) in a baboon following GTKO/CD46 pig-to-baboon kidney transplantation.
The baboon was killed with a functioning graft (serum creatinine 2.0 mg/dL) on day 16 (top). Microscopic examination of the kidney at necropsy showed no or minimal 
deposition of IgM, IgG, or C3, no cellular infiltrates, but some deposition of fibrin (bottom) Copyright © 2012 John Wiley and Sons. Reproduced with permission of Lin CC, 
Ezzelarab M, Shapiro R, et al. Tissue factor expression on recipient platelets is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. 
Am J Transplant. 2010;10(7):1556–1568.34
Abbreviation: TF, tissue factor.
Figure 5 Insulin immunostaining of liver section in a streptozotocin-induced diabetic 
monkey recipient 1 year after transplantation of islets from an adult CD46-transgenic pig.
Blood glucose levels had remained normal throughout this period without the 
need for any exogenous insulin therapy Copyright © 2012 John Wiley and Sons. 
Reproduced with permission of  van der Windt DJ, Bottino R, Casu A, et al. Long-
term controlled normoglycemia in diabetic non-human primates after transplantation 
with hCD46 transgenic porcine islets. Am J Transplant. 2009;9(12):2716–2726. .
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to some extent from the immune response of the host. In 
these cases, exogenous immunosuppressive therapy is not 
required. Survival of more than 6 months has been achieved 
in nonhuman primates,68,69 but it is uncertain whether the graft 
subsequently fails from ischemia or a slow immune response. 
The minimal risk to the patient (in the absence of the need 
for immunosuppressive therapy) has enabled clinical trials to 
be initiated.70
There are several million patients worldwide with 
neurodegenerative diseases who might benefit from the 
transplantation of specif ic neuronal cells. Long-term 
(.1 year) survival of pig neuronal cell xenotransplantation 
in the treatment of monkeys with an induced Parkinson-like 
condition has also been achieved by the transplantation 
of fetal pig dopamine-producing cells that transgeni-
cally express CTLA4-Ig, a potent costimulatory blockade 
molecule.71
Although in the Western world the availability of deceased 
human corneas meets the needs of clinical corneal transplan-
tation, worldwide there is a major deficiency5 (Table 5). As 
the cornea is a relatively avascular structure and therefore 
less susceptible to antibody binding and complement activa-
tion,5 wild-type pig corneal xenotransplantation in nonhuman 
primates has also been associated with relatively long-term 
graft survival.72,73 Importantly, this has been achieved with 
only local corticosteroid therapy to the eye. The availability 
of genetically engineered pigs should increase corneal graft 
survival further.
The potential of red blood cell xenotransfusion from 
genetically engineered pigs into patients is also being 
investigated.74,75 Red blood cells from genetically modified 
pigs have been demonstrated to be preferable to ABO-
incompatible allotransfusions, but not yet comparable to 
ABO-compatible transfusions. As red blood cells do not 
have nuclei, modifications to the standard techniques of 
genetic engineering are required before this can be entirely 
 successful. However, it is likely that the pig will eventu-
ally become a limitless source of blood for transfusion, 
particularly in countries where a high incidence of human 
immunodeficiency virus infection has greatly reduced the 
availability of human donor blood.
Other immunological considerations
In addition to Gal, pigs express another known carbohy-
drate antigen, namely N-glycolylneuraminic acid (NeuGc), 
which is also expressed in all nonhuman primates, but not 
in humans.76–79 Humans are therefore the only mammals 
that develop natural preformed anti-NeuGc antibodies. The 
effect of this antigen–antibody binding therefore cannot be 
tested in nonhuman primate models. Although the effect 
of the presence of NeuGc antigens is not considered to be 
as powerful as that of Gal antigens, nevertheless they do 
provide a target for binding of natural antibodies and for 
subsequent sensitization that may be problematic, at least 
in some patients. It is therefore possible that, particularly 
for organ transplants, pigs that do not express NeuGc may 
be required.
Other important points for which there is some evidence 
are that sensitization to human leukocyte antigens would 
not be detrimental to the outcome of clinical pig organ 
xenotransplantation80 and sensitization to pig antigens after 
clinical pig organ xenotransplantation would not preclude 
subsequent allotransplantation.80
Physiological aspects of 
xenotransplantation
Even if all of the immune barriers and coagulation discrep-
ancies can be overcome, the question remains as to whether 
the various pig organs will function adequately in a primate 
environment. There are several differences in anatomy and 
physiology between pig and primate that may result in less-
than-perfect function.1,81–83
However, evidence from experience of pig orthotopic heart 
transplantation in nonhuman primates, suggests that cardiac 
function will be adequate.43,44 Conclusions with regard to 
function of transplanted pig kidneys need to be cautious, as 
proteinuria is almost always present;29,34 this may be a result 
of immune activation or injury, but other pathophysiological 
causes have not been ruled out. Pig liver function appears to 
be surprisingly good, but as follow-up has been restricted 
Table 5 Estimated numbers of corneal allotransplants carried out 
in 2008 and numbers of patients awaiting corneal transplantation 
in selected countries*
Country Estimated number  
of cases per year
Waiting list
United States 41,652 Minimal
United Kingdom 2711 500
South Africa** 330 1884
India 15,000 300,000
China 101 4,000,000
Taiwan 263 637
Korea 480 3630
Japan 1634 2769
Australia 1096 Minimal
Notes: From Hara and Cooper5; *Based on eye bank data in individual countries and 
personal communications; **in sub-Saharan Africa, the number of corneal transplants 
carried out annually has been falling for several years because of the high incidence of 
human immunodeficiency virus positivity in the potential donor population.
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to approximately a week (because of the development of 
profound thrombocytopenia), definite conclusions cannot be 
drawn.45–47 Pig lung function cannot be adequately assessed, 
as injury is so rapid. Although there are some differences in 
glucose metabolism between pigs and primates,84 pig islet 
function in nonhuman primates is clearly adequate if enough 
islets survive the initial IBMIR.64 It should be noted that nonhu-
man primates have higher insulin requirements than humans 
and pigs, which makes them a more challenging preclinical 
model for pig islet xenotransplantation studies.84
Clinical trials of xenotransplantation
Although progress has been slow, encouraging progress has 
been made during the past 20 years since the initial intro-
duction of genetically engineered pigs and the availability 
of costimulatory blockade immunosuppressive agents. The 
longest survivals of organs and cells in preclinical models 
now extend to approximately 8 and greater than 12 months, 
respectively (Table 6).
Risk–benefit ratio
It will be important to confirm these encouraging results in 
clinical trials, and considerable thought has been given to 
the basis on which these trials can be justified. In particular, 
there has been careful consideration of what results would 
be required to warrant clinical trials of pig heart85 and pig 
islet xenotransplantation.86 Furthermore, the ‘ideal’ patients 
who might be considered for these initial trials are being 
carefully considered.85,87,88
The ethics of performing clinical trials are largely based 
on a calculation of the risk–benefit ratio of the procedure, 
particularly with regard to the potential risk of exposing the 
patient and possibly members of the community to a porcine 
infection (see below).89–91
Thought is therefore being given to clinical trials of 
cell or corneal xenotransplantation, where survival of the 
graft is anticipated to be likely and the risks minimal, rather 
than to clinical trials or organ xenotransplantation, where at 
present the benefits cannot be guaranteed and the risks are 
certainly greater.
For example, there are several million patients worldwide 
who could benefit from a corneal transplant,5 but human 
corneas are not available to them. The risks associated with 
pig corneal xenotransplantation are considered to be low; 
if a pig corneal graft should fail, the patient would remain 
with corneal blindness, but it is unlikely there will be any 
life-threatening complications from this procedure. Again, 
if pig islet transplants are carried out, particularly if they are 
encapsulated and therefore no immunosuppressive therapy 
is required, the risks are likely to be few. Failure of the 
graft would necessitate the patient returning to daily insulin 
therapy, but other complications are unlikely to be seen, at 
least based on our experience in nonhuman primates. It is 
therefore highly likely that corneal, islet, or neuronal cell 
transplants will be the first to enter clinical trials. Indeed, 
under the supervision of the Department of Health in New 
Zealand, there is a clinical trial being undertaken at present 
of encapsulated porcine islets in patients with diabetes.70
With regard to organ transplants, however, the current risks 
are significantly higher. The development of a consumptive 
coagulopathy could, of course, be life-threatening. Even in the 
presence of good graft function, a risk of consumptive coagul-
opathy would contraindicate a clinical trial. The only possible 
exception to this would be if the organ were transplanted for 
a limited period of time as a bridge to  allotransplantation. For 
example, a patient with fulminant hepatitis may die within 
48–72 hours after admission to hospital. If he/she could be 
maintained by an orthotopically transplantated pig liver for 
this period while a human liver was obtained, this might well 
be life-saving.92 A clinical trial may therefore be justified if 
preclinical work indicates that a pig liver will function consis-
tently without major complication for periods of greater than 
1 week. At present (as mentioned above), this is not the case, 
as transplantation of a pig liver into a baboon is followed by an 
almost immediate thrombocytopenia, which could prove life-
threatening, particularly if allotransplantation were attempted 
in the relative absence of platelets.47
The potential risk of transfer of pig 
microorganisms
The other major consideration with regard to potential 
complications from clinical xenotransplantation relates 
Table 6 Approximate maximum periods of survival of pig organs 
and cells in nonhuman primates (without retransplantation)
Organ/cells Period of graft or  
recipient survival
Neuronal cells .1 year
Free pancreatic islets .1 year
Cornea .1 year
Microencapsulated pancreatic islets .8 months
Hepatocytes .8 months
Heterotopic (non-life-supporting) heart ,8 months
Life-supporting kidney ,3 months
Orthotopic (life-supporting) heart ,2 months
Life-supporting liver 9 days
Life-supporting lung 5 days
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to the potential risk of the transfer of a porcine virus, 
microorganism, or parasite with the donor organ into the 
recipient and, possibly of greater importance, from the 
recipient to the general population.93 Risk of such an infec-
tious complication will be minimized by barrier housing of 
the organ-source pigs and by monitoring for the presence 
of infectious organisms at intervals before the organs or 
cells are recovered for transplantation. It would seem that 
the majority of potentially infectious porcine microorgan-
isms, though perhaps not all, can be eradicated from the 
donor herd by careful husbandry techniques, such as early 
weaning and barrier housing.93,94 The potential risks of 
xenotransplantation in this respect are therefore considered 
to be low.95
However, the presence of porcine endogenous retro-
viruses (PERV) in the genome of all pig cells has caused 
concern.96 Although human cells include similar endogenous 
retroviruses that do not appear to cause humans significant 
health problems, the issue has been raised about the potential 
transfer of PERV into human hosts, with possible recom-
bination of porcine and human retroviruses to form new 
viruses. However, to date there has been no evidence of 
transmission of PERV into humans or nonhuman primates 
following porcine organ, tissue, or cell xenotransplantation 
procedures.93,96 It is now thought unlikely that these viruses 
will be problematic. Furthermore, if the actual risk proves 
to be greater than presently thought, genetic engineering 
techniques are available to inhibit activation of porcine 
endogenous retroviruses.97,98
Regulation of clinical xenotransplantation
It is unlikely that national and international regulatory 
authorities, such as the Food and Drug Administration in 
the USA, will prohibit clinical xenotransplantation on the 
basis of the potential risk of infection alone, though they 
will insist on careful monitoring of the organ-source animals 
and of the human recipients for many years following the 
transplant procedure.91,99,100
It should be borne in mind that in comparison with the 
transplantation of human organs from donors who have been 
identified only within the previous few hours and in whom 
monitoring for all infectious agents is not possible during 
this very short period of time, clinical xenotransplantation is 
likely to be a safer procedure. If consistent successful func-
tion of a pig organ or cell transplant in a nonhuman primate 
recipient can be obtained, it is likely that clinical trials will 
be equally successful.
Conclusion
Within the next few years, further clinical trials of xeno-
transplantation will almost certainly be undertaken. The 
likely sequence of clinical trials is outlined in Table 7. 
 Initially, these may involve transplantation of corneas, islets, 
and neuronal cells. During this period, as new improved 
genetically engineered pigs become available, we predict 
it will become justified to carry out organ xenotransplants 
as bridges to allotransplantation, eg, involving the liver or 
heart. Finally, organ xenotransplantation will be carried out 
as a definitive procedure, anticipating relatively long-term 
graft survival. Even if the survival of the graft is not as long 
as that of an allograft, the limitless availability of organ-
source pigs will enable retransplantation to be carried out 
whenever indicated.
It should be remembered that allotransplantation, which 
really began in the early 1950s, has taken 60 years to reach 
its present state of success, even though problems remain, 
particularly with regard to long-term graft survival (chronic 
rejection) and the complications of long-term immunosup-
pressive therapy. The goal of inducing a state of immuno-
logical tolerance to the graft has been elusive, but may be 
easier to achieve in xenotransplantation where the donor 
can be identified and the timing of any pretreatment and the 
operative procedure planned well in advance.
It is exceedingly unlikely that clinical xenotransplantation 
will be successful overnight. There will be a distinct learning 
curve, with steady improvement in results over many years, 
in part relating to the availability of ‘better’ pigs with more 
advanced genetic manipulations, before pig cells and organs 
can routinely replace human cells and organs for these life-
saving procedures. Nevertheless, we predict that eventually 
allotransplantation will become of historical interest only.
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